Morningstar - TiVo Corp. (TIVO) TiVos IP licensing business will sustain the firms excess returns on invested capital.

Report

Morningstar

Andrew Lange

EUR 101.80 For Business Accounts Only

TiVo's IP licensing business will sustain the firm's excess returns on invested capital.

TiVo reported a strong end to fiscal 2016 with the firm signing significantly important intellectual property, or IP, licensing deals with Samsung, Netflix, and HBO. In addition, TiVoâ€™s products business attracted several service provider customers. With TiVo and Rovi now operating as one, management believes the company has the wherewithal to initiate a dividend. Therefore, the company will pay its first quarterly dividend of $0.18 per share during the first quarter of fiscal 2017. The dividend...

16/02/2017 12 EN

Underlying

TiVo Corp.

TiVo is engaged in media and entertainment products. The company provides a set of cloud-based services, embedded software solutions and intellectual property that enable people to find and enjoy online video, television programming, movies and music entertainment, including content discovery through device-embedded and cloud-based user experience, interactive program guides, digital video recorders, natural language voice and text search, cloud-based recommendations services and the company's entertainment metadata. The company's operations are organized into two reportable segments: Product and Intellectual Property Licensing.

See profile

US88870P1066 United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Andrew Lange

Other Reports on these Companies

BusinessWire

TiVo Announces Pioneering Research Partnership with University of Waterloo

SAN JOSE, Calif.--(BUSINESS WIRE)-- TiVo (NASDAQ: TIVO), the company that brings entertainment together, today announces an innovative partnership with the University of Waterloo that will begin with a project investigating methods to enhance the user quality-of-experience for 360º omnidirectional video on head-mounted devices. The research will be led by the University of Waterloo’s Professor Zhou Wang, whose research includes signal and image processing, computational vision and pattern analysis, multimedia coding and communications, and biomedical signal and image processing. The first ph...

May 14, 2020 May 14, 2020 1 EN

TheScreener

Thanks to a better fundamental star rating, TIVO CORP. sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to TIVO CORP. (US), active in the Broadcasting & Entertainment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date December 6, 2019, the closing price was USD 8.38 and its expected value was estimated at USD 7.79.

Free Trial

December 7, 2019 December 7, 2019 6 EN

Valens Research

Valens Equity Insights and Inflections - 2019 04 03

MNK currently trades near historical lows relative to UAFRS-based (Uniform) Earnings, with a 6.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to decline from a record high of 44% in 2017 to 10% through 2022, accompanied by 6% Uniform Asset growth going forward. Meanwhile, analysts have less bearish expectations, projecting Uniform ROA to decline to 36% through 2019, accompanied by 1% Uniform Asset growth. However, management is confident about their Achtar sales growth, ongoing studies, and ability to sustain free cash flow. Should MNK just sustain profi...

April 3, 2019 April 3, 2019 24 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

TiVo's IP licensing business will sustain the firm's excess returns on invested capital.

TiVo Announces Pioneering Research Partnership with University of Waterloo

Thanks to a better fundamental star rating, TIVO CORP. sees an upgrade to Neutral

Valens Equity Insights and Inflections - 2019 04 03

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe